Cytokinetics has released full data from its late-stage MAPLE-HCM trial, demonstrating that the cardiac myosin inhibitor aficamten surpasses standard beta blocker therapy in improving exercise capacity among patients with hypertrophic cardiomyopathy (HCM). The drug showed a notable gain in peak oxygen uptake compared to a decline with metoprolol. These data support aficamten's potential to become a new standard of care and expedite its FDA review process. The trial's outcomes were presented at ESC Congress 2025 in Madrid.